The involvement of C5a in the progression of experimental arthritis with Porphyromonas gingivalis infection in SKG mice

Syuichi Munenaga, Kazuhisa Ouha, Yuta Hamamoto, Mikihi Kajii, Katsuhiro Takeda, Satoshi Yamasaki, Toshihisa Kawai, Noriyoshi Mizuno, Tsuyoshi Fujita, Eiji Sugiyama and Hidemi Kurihara

Abstract

**Background:** Epidemiological evidence to suggest that periodontal disease (PD) is involved in the progression of rheumatoid arthritis (RA) is increasing. The complement system plays a critical role in immune responses. C5a has been implicated in chronic inflammatory diseases, including PD and RA. *Porphyromonas gingivalis* is the major causative bacteria of PD and can produce C5a. Therefore, it is hypothesized that *P. gingivalis* infection is involved in the progression of RA by elevating C5a levels. In the present study, *P. gingivalis*-infected RA model mice were established to investigate the involvement of C5a.

**Methods:** SKG mice orally infected with *P. gingivalis* were immunized with intraperitoneal injection of laminarin (LA) to induce arthritis. Arthritis development was assessed by arthritis score (AS), bone destruction on the talus, histology, and serum markers of RA. In order to investigate the effects of serum C5a on bone destruction, osteoclast differentiation of bone marrow mononuclear cells was examined by using serum samples from each group of mice. The relationship between C5a levels and antibody titers to periodontal pathogens in patients with RA was investigated by enzyme-linked immunosorbent assay.

**Results:** *P. gingivalis* oral infection increased AS, infiltration of inflammatory cells, bone destruction on the talus, and serum markers of RA in mice immunized with LA. The addition of serum from LA-injected mice with the *P. gingivalis* oral infection promoted osteoclast differentiation, and the addition of a neutralization antibody against C5a suppressed osteoclast differentiation. C5a levels of serum in RA patients with positive *P. gingivalis* antibody were elevated compared with those in RA patients with negative *P. gingivalis* antibody.

**Conclusions:** These results suggest that *P. gingivalis* infection enhances the progression of RA via C5a.

Keywords: Arthritis, C5a, *Porphyromonas gingivalis*, SKG mice

**Background**

Rheumatoid arthritis (RA) is a systemic autoimmune disease that leads to synovial inflammation, cartilage damage, and bone destruction [1, 2]. In recent years, the involvement of periodontal disease (PD) in the pathogenesis of RA has attracted attention. PD is characterized by chronic inflammation due to interactions between periodontopathogenic bacteria and host immune responses. Periodontopathogenic bacteria are composed of a group of Gram-negative anaerobic organisms. *Porphyromonas gingivalis*, *Treponema denticola*, and *Tannerella forsythia* play a central role in the pathogenesis of PD and these bacteria are the so-called “red complex” [3]. Previous studies evaluated the systemic effects of PD [4, 5]. RA and PD have immunologically common features. Both disease conditions involve inflammatory cytokines, T helper 17 (Th17) cells, and osteoclast-mediated bone destruction.
Complement plays an important role in host defenses and inflammation by affecting innate and adaptive immune cells [12]. The involvement of the complement system in the pathogenesis of both diseases seems to be important. There are three pathways of complement activation: the classic pathway, lectin pathway, and alternative pathway. All three pathways result in the generation of C3 convertase, which leads to the activation of effector molecules such as C3a and C5a. C5a mediates the recruitment and activation of myeloid cells such as neutrophils, monocytes, and macrophages via C5aR. Among complement factors, C5a is the most powerful effector molecule and has been implicated in chronic inflammatory diseases, including PD and RA [13, 14]. A large number of studies support the C5a–C5aR axis being a critical factor for both diseases.

In patients with RA, the amount of C5a and number of C5aR-positive cells were found to be increased in synovial tissues [15, 16]. C5aR-deficient mice and C5aR antagonist (C5aRA; PMX53)-treated mice in a collagen-induced arthritis (CIA) model, which is a classic model of inflammatory arthritis, were shown to be resistant to synovial inflammation and bone destruction in joints [17, 18]. In PD, when mouse models of P. gingivalis–induced periodontitis were locally treated with a C5aRA, gingival inflammation and alveolar bone destruction were significantly less severe than in the same model without C5aRA [19, 20]. P. gingivalis generates biologically active C5a by its Arg-specific gingipains that have C5 convertase-like activity [21]. Therefore, P. gingivalis can interfere with host immunity, leading to the development of PD. Furthermore, C5a is known to be involved in bone immunopathology. C5a may induce osteoclast differentiation from blood mononuclear cells, and C5aR is required for osteoclast differentiation [22, 23]. Hence, C5a may function as a key factor in the potential link between the two diseases and have important implications for therapeutic approaches against them. As such, the involvement of C5a with P. gingivalis infection in the progression of RA needs to be clarified.

SKG mice, in which a point mutation of the gene encoding ZAP-70 exists on the BALB/c background, develop an arthritis whose features closely resemble those of human RA [24]. Our group previously reported that arthritis was exacerbated in SKG mice infected with P. gingivalis via intraperitoneal (i.p.) injection. One of the underlying mechanisms was the promotion of osteoclast differentiation [25]. Arthritis in SKG mice was induced by an injection of β-glucan, such as laminarin (LA) [26]. β-glucan activates innate immunity and the complement pathway, leading to the generation of C5a. C5a signaling induces the development of Th17 cells, which play a critical role in the development of arthritis through the induction of cytokines such as interleukin-1beta (IL-1β), IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF) in macrophages [27]. C5aR-deficient SKG mice inhibit arthritis and Th17 cell development. Therefore, the C5a–C5aR axis plays an important role in regulating Th17-mediated autoimmune arthritis.

In the present study, we hypothesized that the C5a elevation in P. gingivalis infection is involved in the progression of RA. To test this hypothesis, SKG mice with P. gingivalis oral infection were established and investigated whether P. gingivalis oral infection affects the development of experimental arthritis via elevations in C5a levels. In addition, the association between antibody titers to P. gingivalis and C5a levels in patients with RA was examined.

**Methods**

**Preparation of bacteria**

P. gingivalis W83 was purchased from the American Type Culture Collection (Manassas, VA, USA). P. gingivalis W83 was cultured on a sheep blood agar plate at 37 °C using the Anaeropack system (Mitsubishi Gas Chemical, Tokyo, Japan). After a 2-day incubation, P. gingivalis W83 was inoculated in 40 mL of trypticase soy broth supplemented with 1% yeast extract, hemin (200 μg), and menadione (20 μg). Bacteria were harvested in the exponential growth phase and washed with phosphate-buffered saline (PBS).

**Induction of arthritis and periodontitis**

Female 6- to 8-week-old SKG mice (Clea Japan, Inc., Tokyo, Japan) were immunized by an i.p. injection of LA (Sigma-Aldrich, St. Louis, MO, USA, 10 mg/100 μL/mouse) to induce arthritis. Periodontitis was also induced in SKG mice by an oral inoculation of 10⁵ colony-forming units P. gingivalis W83. P. gingivalis W83 was suspended in 50 μL of PBS containing 2% carboxymethylcellulose (CMC) and inoculated repeatedly every 3 days for 42 days. This term was set in accordance with a previous bone resorption mouse model infected by P. gingivalis [19]. The number of administered bacteria was determined by considering body weight and the number of bacteria in the saliva of patients with periodontitis.
Mice were divided into four groups (Ctrl group: PBS administration; Pg group: Pg inoculation; LA group: LA injection; Pg/LA group: Pg inoculation + LA injection). Animal experiments were approved by the ethics committee of Hiroshima University (approval A12–15). All experiments were performed three times (n = 6 per group).

Assessment of periodontitis
In order to measure alveolar bone loss (ABL), maxilla halves were assessed as described previously [28].

Measurement of antibody titers to periodontopathogenic bacteria
Antibody titers to periodontopathogenic bacteria (P. gingivalis, Prevotella intermedia, Treponema denticola, Tannerella forsythia, and Aggregatibacter actinomycetemcomitans) were measured by enzyme-linked immunosorbent assay (ELISA). The antigens of the fraction of outer membrane proteins from periodontopathogenic bacteria were coated onto 96-well Maxisorp Nunc Immunoplates (Nunc, Roskilde, Denmark) in sodium bicarbonate buffer, pH 9.4, overnight at room temperature (RT). After blocking each well with 1% bovine serum albumin (BSA) in PBS supplemented with 0.05% Tween 20 (PBST) at RT for 1 h, human serum (3200-fold dilution) or mouse serum (100-fold dilution) were applied to each well at RT for 2 h. Wells were washed three times by PBST and incubated with a human or mouse horseradish peroxidase (HRP)-conjugated secondary antibody (2000-fold dilution in PBST) at RT for 1 h. After blocking each well with 1% bovine serum albumin (BSA) in PBS supplemented with 0.05% Tween 20 (PBST) at RT for 1 h, human serum (3200-fold dilution) or mouse serum (100-fold dilution) were applied to each well at RT for 2 h. Wells were washed three times by PBST and incubated with a human or mouse horseradish peroxidase (HRP)-conjugated secondary antibody (2000-fold dilution in PBST) at RT for 1 h. After the final washes, citrate-phosphate buffer, pH 5.0, containing 0.3% hydrogen peroxide and 0.25% o-phenylenediamine was added. The coloring reaction was allowed to continue for 15 min and was stopped by the addition of 25 μL of 2 N sulfuric acid. Absorbance at 405 nm was measured by using a plate reader (Bio-Rad Laboratories, Hercules, CA, USA).

Clinical assessment of experimental arthritis
Arthritis score (AS) was monitored weekly and recorded using a previously published system [24]: 0, no swelling or redness; 0.1, swelling or redness of the digits; 0.5, mild swelling or redness (or both) of the wrist or ankle joints; 1, severe swelling of the large joints. Scores of the affected joints were totaled for each mouse; the maximum total score per mouse was 6.0, and the minimum was 0.

Histological examination
Ankle joints were isolated at the end of the experiment in 4% paraformaldehyde for 24 h, decalcified in 10% ethylene diamine tetrameric acid (EDTA) for 42 days, and embedded in paraffin. Seven-micrometer-thick tissue sections were stained with hematoxylin and eosin (HE), Safranin O, and a tartrate-resistant acid phosphatase (TRAP) staining kit (Takara Bio, Inc., Shiga, Japan). The severities of inflammation and cartilage damage were scored using published criteria [29]. The number of TRAP-positive cells in a randomly selected diseased site (three sites per picture) was counted and compared among the different groups.

Micro-computed tomography analysis
In the micro-computed tomography (micro-CT) analysis, mice were scanned by using a Skyscan 1076 (Bruker, Kontich, Belgium) to evaluate bone destruction. Joint samples were scanned and reconstructed at 18 μm3 voxels by using a micro-CT system.

Measurement of the factors in serum by ELISA
ELISAs for human C5a (#DY2037; R&D, Minneapolis, MN, USA), mouse C5a (#EK0987; Boster, Pleasanton, CA, USA), mouse IL-6 (#431304; BioLegend Inc., San Diego, CA, USA), mouse matrix metalloproteinase-3 (MMP-3, #MMP300; R&D), and mouse anti-citrullinated protein antibody (ACPA) (#ORG601 Orgentec, Chicago, IL, USA) in serum were performed in accordance with the instructions of the manufacturers. The limits of detection for each analyte were as follows: human C5a, 31.3 pg/mL; mouse C5a, 15.6 pg/mL; mouse IL-6, 7.8 pg/mL; mouse MMP-3, 0.312 ng/mL; and mouse ACPA, 0 U/mL.

Immunohistochemical analysis
Fixed tissues were embedded in paraffin wax, at a thickness of 7 μm, mounted on slides. Slides were incubated with a primary goat polyclonal antibody for C5a (sc-21,944; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 4 °C overnight. Slides were then washed three times in PBST and incubated with a goat HRP-conjugated secondary antibody (1:200) at RT for 1 h. After three washings, color development was achieved with 3,3′-diaminobenzidine. Photographs were taken with a Nikon Eclipse E600 (Nikon, Tokyo, Japan).

Collection of bone marrow mononuclear cells
Bone marrow mononuclear cells (BMCs) from the femurs of SKG mice were isolated by density gradient centrifugation with Histopaque-1083 (Sigma-Aldrich) in complete Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), antibiotics (penicillin, streptomycin, and gentamicin; Invitrogen), and L-glutamine.

Quantitative RT-PCR
Total RNA was extracted from the liver and BMCs by using RNAiso (Takara Bio, Inc.) in accordance with the protocol of the manufacturer. Briefly, one microgram of total RNA was used for reverse transcription by
ReverTra Ace® for reverse transcription-polymerase chain reaction (RT-PCR) (cat. no. TRT-101, Toyobo, Osaka, Japan). Real-time PCR was performed by StepOne Plus (Applied Biosystems, Carlsbad, CA, USA). Amplification conditions were described previously [30]. Template cDNA was mixed with the Core Reagent Fast SYBR® Master Mix system (Applied Biosystems), distilled water, and a primer (10 pmol). The following primer sets were used for real-time PCR: C5 forward, 5′-TTTC AGCACCCAAAATCCTC-3′ and C5 reverse, 5′-CGCG TTTGGAATTTGTTTT-3′; tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) forward, 5′-CTGCAAAGCCTTGACATC-3′ and TRAF6 reverse, 5′-AATGTGTGTATTAACCTGGC-3′; nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) forward, 5′-TCATCCTGTCACACACAAA-3′ and NFATc1 reverse, 5′-TTGCCGAAAAGTGTATCTC-3′; MMP-9 forward, 5′-CTGGACAGCACCACACTAAAG-3′ and MMP-9 reverse, 5′-CTCGCGCCAGTCTTCCAGA G-3′; 18s rRNA forward, 5′-GTAACCCGTTGAAC CCCATT-3′ and 18s rRNA reverse, 5′-CATCCCAA CGGTATGAGC-3′. Relative expression levels were calculated by standard curve methods and ΔΔCt methods, and 18S ribosomal RNA was used as the internal control.

**Osteoclast differentiation and resorption assay**

BMCs were seeded on 96-well plates for osteoclast differentiation assay or osteo assay plates for resorption assay at a density of 1.0 × 10^5 cells per well and cultured in alpha-modified Eagle’s minimum essential medium (α-MEM) with 15% FBS containing 20 ng/mL M-CSF (#315–02; Peprotech, Rocky Hill, NJ, USA) and 50 ng/mL murine soluble recombinant receptor activation of nuclear factor kappa-B ligand (sRANKL, #315–11; Peprotech). After 2 days, BMCs were cultured in the presence of 20 ng/mL M-CSF and 50 ng/mL sRANKL with 10% FBS and 5% mouse serum for 3 days. Sera were prepared from each group of mice. In regard to the neutralization of C5a, 0.5 μg/mL anti-mouse C5a antibody (#MAB21501; R&D) or rat IgG2 isotype control (#MAB006; R&D) was added to the culture medium. After 3 days, differentiated osteoclasts were identified by TRAP staining and TRAP-positive multinucleated (more than three nuclei) cell numbers were evaluated. Resorption areas were measured by ImageJ after removal of the cells with 1 M NH₄OH.

**Participants**

Sera were collected from 40 patients at the Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital. All of the patients with RA fulfilled the 2010 American College of Rheumatology criteria for RA.

**Ethics approval**

All patients provided written informed consent prior to enrollment. This study was approved by the ethics committee of Hiroshima University Hospital (#1017).

**Evaluation of antibody titers of patients by ELISA units**

The antibody titers to periodontal pathogens in human were expressed as ELISA units. ELISA units were measured as described previously [31]. A positive antibody response was defined as a standard deviation of more than 2 above the mean ELISA units of the age-similar healthy hospital personnel.

**Statistical analysis**

Data are expressed as the mean ± standard error of the mean. Statistical analyses between two groups were performed using the Mann–Whitney U test in the case of a non-normal distribution. For multiple comparisons, the Tukey-Kramer test or Bonferroni-corrected Mann–Whitney U test was used. Pearson’s or Spearman’s correlation coefficient was calculated for the correlations performed. In all tests, a P value of less than 0.05 was considered significant.

**Results**

**Periodontitis induced by *P. gingivalis* oral infection increases the severity of experimental arthritis**

In order to evaluate the induction of periodontitis, ABL and antibody titers to *P. gingivalis* in SKG mice after the oral infection of *P. gingivalis* were analyzed. The severity of ABL was remarkably greater in the Pg and Pg/LA groups than in the Ctrl and LA groups (Pg group: 125 ± 2.68% increase, Pg/LA group: 130.7 ± 7.86% increase against Ctrl, respectively) (Fig. 1a, b). The inoculation of the Pg and Pg/LA groups resulted in an increase in antibody titers to *P. gingivalis* in serum (Pg group: 2.32 ± 0.34-fold increase, Pg/LA group: 2.92 ± 0.43-fold increase against Ctrl, respectively) (Fig. 1a, b). The inoculation of the Pg and Pg/LA groups resulted in an increase in antibody titers to *P. gingivalis* in serum (Pg group: 2.32 ± 0.34-fold increase, Pg/LA group: 2.92 ± 0.43-fold increase against the Ctrl group, respectively) (Fig. 1c). However, no significant differences were observed between the Pg and Pg/LA groups. These results indicate that *P. gingivalis* oral infection induces periodontitis in SKG mice.

In order to examine the pathophysiological role of *P. gingivalis* oral infection in experimental arthritis, arthritis development was assessed in each group. The AS and incidence of arthritis were higher in the Pg/LA group than in the other groups in a time-dependent manner (Fig. 1d–f) (Ctrl group: 0.13 ± 0.07; Pg group: 0.15 ± 0.07; LA group: 1.2 ± 0.14; Pg/LA group: 3.6 ± 0.64). In order to investigate the influence of *P. gingivalis* oral infection on bone loss in joints, the bone properties of the talus as a parameter of focal bone loss were analyzed. Bone erosion of the talus in the Pg/LA group was
observed in the micro-CT analysis (Fig. 1g). Talar bone volume was lower in the Pg/LA group than in the other groups (Ctrl group: 1.4 ± 0.08 mm³; Pg group: 1.36 ± 0.13 mm³; LA group: 1.35 ± 0.13 mm³; Pg/LA group: 1.11 ± 0.09 mm³), and the percentage of reduction in bone volume relative to the Ctrl group was the highest in the Pg/LA group (20.4 ± 3.19%) (Fig. 1h, i). Although the ankle joint was inflamed in the LA group, bone erosion, which was assessed using a micro-CT analysis, was not observed. Furthermore, increase of IL-6 and MMP-3 production in serum was greater in the Pg/LA group than in the other groups (IL-6: 54.3 ± 16.6 pg/mL; MMP-3: 118.6 ± 19.6 ng/mL) (Fig. 1j, k). The correlation between the production of ACPA in serum of Pg/LA group and anti-Pg antibody titer was analyzed. A positive correlation was observed (r = 0.797, P = 0.018) (Fig. 1l). These results suggest that *P. gingivalis* oral infection...
exacerbates experimental arthritis and bone destruction in SKG mice.

**Impact of *P. gingivalis* oral infection on the histopathology of arthritis**

Histopathological changes in the ankle joint by HE staining, Safranin O staining, and TRAP staining were not observed in the Ctrl or Pg group (Fig. 2a). Inflammation, cartilage damage, and bone destruction were more severe in the Pg/LA group than in the other groups (Fig. 2a). These evaluation points were quantified by using a histological scoring system [29]. Inflammation, cartilage damage, and bone destruction in the ankle joint were more severe in the Pg/LA group than in the other groups (inflammation score: 2.67 ± 0.45; cartilage damage score: 2.17 ± 0.28; TRAP-positive cell number: 13.8 ± 8.74) (Fig. 2b–d). These results suggest that *P. gingivalis* oral infection in SKG mice promotes arthritis and leads to the bone destruction phase.

**Production of C5a in the serum and ankle joint**

Previous studies indicated that C5a plays an important role in the progression of RA [17, 18]. Quantitative RT-PCR revealed that the mRNA expression levels of C5 in the liver were increased by *P. gingivalis* infection (Pg group: 2.66 ± 0.53-fold increase; Pg/LA group: 2.66 ± 0.49-fold increase against the Ctrl group, respectively) (Fig. 3a). C5a levels in serum were higher in the Pg and LA groups than in the Ctrl group. The increase of C5a levels observed in the Pg/LA group was prominent (Ctrl group: 19.4 ± 6.1 ng/mL; Pg group: 39.2 ± 3.54 ng/mL; LA group: 33.6 ± 3.57 ng/mL; Pg/LA group: 55.2 ± 1.99 ng/mL) (Fig. 3b). In the Pg/LA group, C5a levels in serum showed a positive correlation with AS and anti-*P. gingivalis* antibody titers (Fig. 3c, d).

Immunohistochemical-based quantification indicated that the positive area of C5a in the Pg/LA group was significantly increased (4.16 ± 0.23%) (Fig. 3e–m). The localization of C5a was close to the area of bone destruction in the punnus (Fig. 3h). These results support C5a...
being involved in bone destruction in inflamed joints in the Pg/LA group.

Effects of C5a derived from serum on osteoclast differentiation

In order to investigate the contribution of C5a to bone destruction, osteoclast differentiation was examined by using BMCs in the presence of C5a. C5a could induce TRAP-positive cells in a dose-dependent manner (Fig. 4a, b). It was confirmed by pit formation assay that these cells have the function of bone resorption (Fig. 4c, d). C5a induced the mRNA expression of NFATc1, which is a master regulator of osteoclastogenesis, in a dose-dependent manner (Fig. 4e). In addition, the mRNA expression of TRAF6 and MMP-9, which are osteoclast-associated markers, were induced (Fig. 4f, g). These results suggest that C5a can induce functional osteoclasts through the elevation of osteoclast-associated transcription factors, including NFATc1.

Furthermore, the addition of serum collected from the Pg/LA group induced functional osteoclasts more effectively than that from the other groups. These effects were blocked by the neutralizing antibody against C5a (Fig. 4h–k), indicating that the high level of C5a in the Pg/LA group was responsible for osteoclast differentiation. These results suggest that elevated C5a levels of serum in the Pg/LA group activate osteoclast differentiation.

Relationship between C5a levels and antibody titers to periodontal pathogens in patients with RA

The demographics of RA participants in the present study are summarized in Table 1. Patients with RA had significantly greater mean C5a levels in serum than healthy control participants (Fig. 5a). There was no significant correlation between C5a levels and C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) in serum (Fig. 5b, c). Thus, it was suggested that C5a was not solely dependent on inflammation in patients with RA. The relationship between C5a levels and antibody titers to periodontal pathogens in patients with RA was investigated. Antibody titers to periodontal pathogens differed among patients. RA patients with positive P. gingivalis antibody responses had significantly elevated C5a levels in serum compared with negative P. gingivalis antibody (Fig. 5d). The higher tendency of the levels of C5a in serum from the group of RA patients with negative Treponema denticola, Tannerella forsythia, and Aggregatibacter actinomyctecomitans antibody was observed compared with serum from the group of positive Treponema denticola,
Tannerella forsythia, and Aggregatibacter actinomycetemcomitans antibody patients. However, there was no statistical difference between positive and negative groups (Fig. 5e–h).

These results suggest that *P. gingivalis* infection increases in C5a levels in patients with RA.

**Discussion**

Epidemiological evidence to suggest that PD is involved in RA is increasing [32, 33]. Patients with RA show a significantly higher antibody response to *P. gingivalis* in comparison with systemically healthy individuals [34]. Serum levels of antibodies to *P. gingivalis* reflect the clinical and laboratory profiles of RA [35]. In addition, periodontal therapy was suggested to reduce the severity of RA as well as serum levels of antibodies to *P. gingivalis* [36]. Therefore, chronic *P. gingivalis* infection may

---

**Table 1** Clinical conditions of participants (n = 40)

| Parameters        | Mean ± standard error |
|-------------------|-----------------------|
| Age, years        | 60.6 ± 1.8            |
| Female, percentage| 65.0                  |
| CRP, mg/dL        | 0.57 ± 0.14           |
| ESR, mm/hr        | 27.0 ± 3.51           |
| VAS score, mm     | 40.5 ± 4.9            |
| RF levels, IU/ml  | 739 ± 13.9            |
| ACPA, U/ml        | 1150 ± 35.3           |

Abbreviations: ACPA anti-citrullinated protein antibody, CRP C-reactive protein, ESR erythrocyte sedimentation rate, RF rheumatoid factor, VAS Visual Analogue Scale

---

**Fig. 4** Bone marrow mononuclear cells (BMCs) were cultured in the presence of macrophage colony-stimulating factor and soluble recombinant receptor activation of nuclear factor kappa-B ligand to promote osteoclast differentiation. a Representative images of osteoclast differentiation with recombinant C5a (rC5a) by tartrate-resistant acid phosphatase staining. b The number of multi-nuclear osteoclast in each well (n = 10). c Representative images of bone resorption in the presence of rC5a by pit formation assay. d Bone resorption area by multi-nuclear osteoclast in each well was measured by ImageJ (n = 8). e–g Quantitative reverse transcription-polymerase chain reaction analysis of NFATc1, TRAF6, and MMP-9 (n = 8). h Representative images of osteoclast differentiation of BMCs by the effect of serum derived from each group of mice in the presence of an isotype control antibody or anti-C5a antibody. i The number of multi-nuclear osteoclast in each well with or without serum derived from each group of mice (n = 10). j Representative images of bone resorption by the effect of serum derived from each group of mice in the presence of an isotype control antibody or anti-C5a antibody. k Bone resorption area by multi-nuclear osteoclast in each well was measured by ImageJ (n = 5). Statistical analyses were performed by the Student’s unpaired *t* test or Tukey-Kramer test (*P* < 0.05). Data represent the mean ± standard error of the mean. Original magnification: 40×; scale bar = 1000 μm.
influence the development of arthritis. *P. gingivalis* is the only human pathogen producing the peptidyl-arginine deiminase (PgPAD). Because of the PgPAD expression, *P. gingivalis* was considered as an important link between PD and RA [37]. However, the mechanisms responsible for this association remain unclear. *P. gingivalis* also has several virulence factors, such as fimbriae, lipopolysaccharide (LPS), and gingipain, which systemically activate immune response. *P. gingivalis* can also induce active C5a generation, which is one of the complement factors, via digestion by gingipain. Therefore, we focused on the involvement of complement in the progression of RA by *P. gingivalis* infection.

The complement system is activated by bacterial infection and inflammatory conditions, leading to the generation of anaphylatoxins such as C5a. Thus, C5a levels may be equally elevated in any of the periodontal pathogenic bacteria. However, our results showed the significantly elevated C5a levels of serum in RA patients with positive *P. gingivalis* antibody compared with that with negative *P. gingivalis* antibody. Moreover, no significant difference was observed between any of the other periodontal pathogens and C5a levels in serum (Fig. 5). Therefore, infection by *P. gingivalis* may have a greater potential to promote the generation of C5a than other periodontal pathogens in patients with RA. In order to account for this relationship, a large-scale clinical study is needed. It currently remains unclear how *P. gingivalis* infection is involved in the activation of C5a-mediated immune responses. Complement activation occurs through three different pathways (classic, lectin, and alternative) after bacterial infection and inflammatory responses as innate immunity [38]. It is possible that a proteinase derived from *P. gingivalis* (gingipain) or the immune complex consisting of bacterial antigens activates the complement cascade [39]. There is a report about the activation of C5a by gingipain [21]. The application of gingipain knockout mutant is a good way to clarify the involvement of C5a in the progression of Pg-induced RA. However, gingipain displays a diversity of effects on host cells, including the increase of attachment to gingival epithelial cells, hemin acquisition for growth, and proteolytical inactivation of cytokine [40]. Therefore, there is a possibility that the inhibitory effect of C5a cannot be observed by knockout mutant which is weak against host immune response.

The CIA model is the most widely accepted mouse model of RA and has contributed to clarify the
pathology of RA. Previous reports indicated that \textit{P. gingivalis} affects the immune system and the gut microbiota composition, leading to the arthritis development in the CIA model [41, 42]. Our group previously reported that \textit{P. gingivalis} infection exacerbates arthritis in SKG mice via the promotion of osteoclast differentiation [25]. The cause of RA is systemic and abnormal immune responses [43]. SKG mice develop arthritis that closely resembles human RA, and arthritis in SKG mice is induced by an injection of \( \beta \)-glucan through the activation of systemic immune cells. Therefore, the use of SKG mice as an RA model has the advantage of inducing systemic immune responses. An i.p. injection of \textit{P. gingivalis} to SKG mice was previously selected in an attempt to simplify the systemic effects of \textit{P. gingivalis} in \textit{in vivo} experiments [25]. However, orally applied bacteria are also known to influence bacterial flora in the digestive tract such as the mouth and gut. Since \textit{P. gingivalis} is periodontopathogenic bacteria, an oral \textit{P. gingivalis} inoculation model needs to be analyzed in order to physiologically investigate the effects of \textit{P. gingivalis} infection.

In the present study, we established that arthritis was augmented by \textit{P. gingivalis} oral infection in SKG mice. Severity of swelling, inflammation, cartilage damage, and bone destruction in joints was observed in the Pg/LA group (Figs. 1 and 2), and the expression of C5a in serum and joint was increased (Fig. 3). The increased expression of C5a by \textit{P. gingivalis} oral infection is a potential cause of the acceleration of arthritis, particularly in the involvement of osteoclast differentiation. We confirmed that C5a can induce functional osteoclasts from BMCs and the mRNA expression of \textit{NFATc1} in a dose-dependent manner. In addition, we demonstrated that the osteoclast differentiation of BMCs was potentiated more by serum from the Pg/LA group than from the other groups (Fig. 4). These results suggest that circulating C5a promotes osteoclastogenesis, leading to bone destruction in joints. However, the biological activity of C5a is potently inhibited by removal of the carboxyl-terminal Arg, which is known as C5a des Arg [44]. Although C5a des Arg has many of the same functions, higher concentrations are needed in order to induce biological effects [45]. Moreover, other cytokines in serum, such as TNF-\( \alpha \), may participate in osteoclast differentiation [46, 47]. In order to validate the direct effects of C5a in serum, a neutralizing antibody against C5a was used in osteoclast differentiation. The osteoclast differentiation of BMCs, which were added to serum from the Pg/LA group, was significantly inhibited by the neutralizing antibody against C5a. Therefore, C5a in serum is involved in osteoclast differentiation. In addition to these results, BMCs that were harvested from arthritic SKG mice by an i.p. injection of \textit{P. gingivalis} differentiated into markedly larger and multinuclear osteoclasts in our previous study [25]. There is a possibility that C5a in serum is involved in this mechanism.

In SKG mice, C5a drives Th17 cell differentiation and triggers autoimmune arthritis [27]. The number of CD4\(^+\) T cells and the Th17/regulatory T (Th17/Treg) ratio in the spleen were higher in the Pg/LA group than in the other groups (data not shown). Therefore, increases in C5a levels by \textit{P. gingivalis} infection may be involved in the exacerbation of arthritis by driving Th17 development.

Clinical findings suggest that ACPA plays an important role in the pathogenesis of RA and correlates with the severity of bone damage in patients with RA [48, 49]. ACPA activates the human complement system via classic and alternative pathways, leading to the release of C5a [50]. Previous studies indicated that elevations in antibodies to \textit{P. gingivalis} are associated with serum levels of ACPA in patients with RA [51]. In the present study, a positive correlation was observed between antibody titers to \textit{P. gingivalis} W83 and serum levels of ACPA, and the Pg/LA group showed an increase in ACPA levels in serum (Fig. 11). Therefore, elevated C5a levels may have been caused by the ACPA, which was generated by PgPAD. In order to investigate this possibility, the construction of a PAD-deficient strain of \textit{P. gingivalis} is needed. It is true that PgPAD is involved in the generation of ACPA. A previous report indicated that a PAD-deficient strain of \textit{P. gingivalis} reduced the level of ACPA in CIA model mice [52]. However, not only the PgPAD but also other pathogenic factors produced by Pg, including gingipain, fimbriae, capsule, and LPS, are possible ACPA-inducing factors. For these reasons, there is a limitation to clarify the involvement of PgPAD by using \textit{P. gingivalis} knockout mutants in the progression of RA.

Previous studies indicated that, besides PD and RA, C5a is related to various diseases, including systemic lupus erythematosus, asthma and allergy, atherosclerosis, Alzheimer’s disease, and glomerulonephritis [53]. PD is a highly prevalent chronic inflammatory disease, and many patients with PD are infected with \textit{P. gingivalis} [54]. PD with \textit{P. gingivalis} infection might affect the exacerbation of these diseases via C5a.

Conclusions

In summary, we demonstrated that oral infection with \textit{P. gingivalis} exacerbated arthritis in the SKG model. Elevations of C5a levels in serum were confirmed in patients with RA and experimental arthritis mice. Elevated C5a levels by an infection with \textit{P. gingivalis} may be partially involved in arthritis via bone destruction by the promotion of osteoclast differentiation. These results suggest that C5a is a target for elucidating the relationship between PD and RA. Further studies are needed in order
to clarify the mechanisms by which infection with *P. gingivalis* increases C5a levels in serum as well as the effects of the control of C5a by the treatment with PD on RA.

**Abbreviations**

ABL: Alveolar bone loss; ACPA: Anti-citrullinated protein antibody; AS: Arthritis score; BMC: Bone marrow mononuclear cell; CSaR: C5aR antagonist; CIA: Collagen-induced arthritis; Ctrl: Control; ELISA: Enzyme-linked immunosorbent assay; FBS: Fetal bovine serum; HE: Hematoxylin and eosin; HRP: Horseradish peroxidase; IL: Interleukin; LP: Lipopolysaccharide; M-CSF: Macrophage colony-stimulating factor; Mi-cro-CT: Micro-computed tomography; MMP: Matrix metalloproteinase; NFATC1: Nuclear factor of activated T cells cytoplasmic 1; PAD: Peptidyl-arginine deiminase; PBS: Phosphate-buffered saline; PBST: Phosphate-buffered saline supplemented with 0.05% Tween 20; PD: Periodontal disease; Pg: *Porphyromonas gingivalis*; PgPAD: *Porphyromonas gingivalis* peptidyl-arginine deiminase; RA: Rheumatoid arthritis; RT: Room temperature; RT-PCR: Reverse transcription-polymerase chain reaction; sRANKL: Soluble recombiant receptor activation of nuclear factor kappa-B ligand; Th17: T helper 17; TNF: Tumor necrosis factor; TRAF6: Tumor necrosis factor receptor-associated factor 6; TRAP: Tartrate-resistant acid phosphatase

**Acknowledgments**

We would like to thank the Medical English Service (Kyoto, Japan) for the helpful support in correcting the grammar of this paper.

**Funding**

This research was supported by Grants-in-Aid for Scientific Research (C) (15 K11390, 18 K095990) from the Japan Society for the Promotion of Science.

**Availability of data and materials**

The datasets used or analyzed (or both) during the present study are available from the corresponding author on reasonable request.

**Authors’ contributions**

KO had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. SM, KO, MK, and HK contributed to conception and design. SM and KO performed in vivo and in vitro experiments. SM, KO, MK, KT, YH, SY, TK, NM, TF, ES, and HK analyzed the results and performed interpretation of data. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Animal experiments were approved by the ethics committee of Hiroshima University Hospital (approval A12-15). All patients provided written informed consent prior to enrollment. This study was approved by the ethics committee of Hiroshima University Hospital (#1017).

**Consent for publication**

The consent of all coauthors was collected before submission.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Periodontal Medicine, Graduate School of Biomedical & Sciences, Hiroshima University, 1–2–3, Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
2. Division of Periodontology, Kurume University Medical Center, 155-1 Kokubu-machi, Kurume 839-0863, Japan.
3. Department of Immunology and Rheumatology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
4. Department of Clinical Science, Nova Southeastern University College of Dental Medicine, 3200 South University Drive, Fort Lauderdale, FL 33328, USA.

**References**

1. McNienes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19.
2. Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther. 2009;11:249.
3. Socransky SS, Haffajee AD. Implications of periodontal microbiology for the treatment of periodontal infections. Compend Suppl. 1994;15:664–5, 668–69; quiz 5714–687.
4. Han YW, Wang X. Mobile microbiome: oral bacteria in extra-oral infections and inflammation. J Dent Res. 2013;92:485–91.
5. Scher AJ, Bretz WA, Abramson SB. Periodontal disease and subgingival microbota as contributors for rheumatoid arthritis pathogenesis: modifiable risk factors? Curr Opin Rheumatol. 2014;26:424–9.
6. Hienz SA, Paliwal S, Ivanovski S. Mechanisms of Bone Resorption in Periodontitis. J Immunol Res. 2015;2015:615486.
7. Boissier MC. Cell and cytokine imbalances in rheumatoid synovitis. Joint Bone Spine. 2011;78:30–4.
8. de Pablo P, Chapple IL, Buckley CD, Dietrich EK, Ricklin D, Lambris JD, et al. Local complement activation. Blood. 2010;116:4456–67.
9. de Pablo P, Dietrich T, McDonld TE. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol. 2008;35:70–6.
10. Chen HH, Huang N, Chen YM, Chen TJ, Chou P, Lee YL, et al. Association between a history of periodontitis and the risk of rheumatoid arthritis: a nationwide, population-based, case-control study. Ann Rheum Dis. 2013;72:206–11.
11. Mileus TR, Thiele GN, Deane KD, Payne JB, ODell JR, Yu F, et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum. 2012;64:3522–30.
12. Ricklin D, Haji-shengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97.
13. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821–52.
14. Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol. 2012;8:458–68.
15. Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemoattractant complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis. 1990;49:474–72.
16. Kienzler JP, Baghestanian M, Dominikus M, Walchaufhofer S, Grannand M, Willhime M, et al. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:233–45.
17. Grant EP, Picarella D, Burwell T, Delaney T, Croci A, Avitahl N, et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med. 2002;196:1461–71.
18. Anderson C, Wenendan CS, Ysher PA, Hebsgaard JB, Sondergaard BC, Rono B, et al. Rapid-onset clinical and mechanistic effects of anti-CSaR treatment in the mouse collagen-induced arthritis model. Clin Exp Immunol. 2014;177:219–33.
19. Liang S, Krauss JL, Domon H, Mcintosh MI, Hosur KB, Qu H, et al. The C5a receptor impair IL-12-dependent clearance of *Porphyromonas gingivalis* and is required for induction of periodontal bone loss. J Immunol. 2011;186:869–77.
20. Abe T, Hosur KB, Haji-shengallis G, Reis ES, Ricklin D, lambris JD, et al. Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist. J Immunol. 2012;185:5442–8.
21. Wingrove JA, DiSciopo RG, Chen Z, Potempa J, Travis J, Hugli TE. Activation of complement components C3 and C5 by a cysteine proteinase (gingipain–I) from *Porphyromonas Bacteroides* gingivalis. J Biol Chem. 1992;267:18902–7.
22. Ignatius A, Schoengraf P, Kreja A, Recknagel S, Kandert S, et al. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL–1beta. J Cell Biochem. 2011;112:2594–605.
23. Tu Z, Wu H, Dennis JE, Lin F. Efficient osteoclast differentiation requires local complement activation. Blood. 2010;116:4456–63.
24. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami Y, Yamazaki S, et al. Altered thymic T-cell selection due to a mutation of the Zap-70 gene causes autoimmune arthritis in mice. Nature. 2003;426:454–60.
25. Yamasaki M, Ohara K, Kajiya M, Munenaga S, Kittaka M, Yamasaki S, et al. Porphyromonas gingivalis infection exacerbates the onset of rheumatoid arthritis in SKG mice. Clin Exp Immunol. 2016;186:177–89.

26. Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, et al. A role for fungal (beta)-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med. 2005;201:949–60.

27. Hashimoto M, Hirota K, Yoshitomi H, Maeda S, Teradaira S, Akizuki S, et al. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J Exp Med. 2010;207:1135–43.

28. Lin X, Han X, Kawai T, Taubman MA. Antibody to receptor activator of NF-kappaB ligand ameliorates T-cell mediated periodontal bone resorption. Infect Immun. 2011;79:911–7.

29. Mukai T, Gallant R, Ishida S, Kittaka M, Yoshitaka T, Fox DA, et al. Loss of SH3 domain-binding protein 2 function suppresses bone destruction in tumor necrosis factor-driven and collagen-induced arthritis in mice. Arthritis Rheumatol. 2015;67:656–67.

30. Shiba H, Tsuda H, Kajiya M, Fujita T, Hino T, et al. Neodymium-doped yttrium-aluminium-garnet laser irradiation abolishes the increase in interleukin-6 levels caused by peptidoglycan through the p38 mitogen-activated protein kinase pathway in human pulp cells. J Endod. 2009;35:373–6.

31. Kudo C, Narushi K, Maeda H, Abiko Y, Hino T, Iwata M, et al. Assessment of Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol. 2015;67:1190–5.

32. Shiba H, Tsuda H, Kajiya M, Fujita T, Hino T, et al. Neodymium-doped yttrium-aluminium-garnet laser irradiation abolishes the increase in interleukin-6 levels caused by peptidoglycan through the p38 mitogen-activated protein kinase pathway in human pulp cells. J Endod. 2009;35:373–6.

33. Kudo C, Narushi K, Maeda H, Abiko Y, Hino T, Iwata M, et al. Assessment of the plasma/serum IgG test to screen for periodontitis. J Dent Res. 2012;91:1190–5.

34. Bender P, Burgin WB, Sculean A, Eick S. Serum antibody levels against Porphyromonas gingivalis in patients with and without rheumatoid arthritis. Arthritis Rheumatol. 2014;66:1090–100.

35. Scher JU, Ubeda C, Equinda M, Khanin R, Buyschi Y, Viale A, et al. Periodontitis and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheumatol. 2016;68:3083–94.

36. Maresz KJ, Hellvard A, Sroka A, Adamowicz K, Bielecka E, Koziel J, et al. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated inflammatory pathways in experimental autoimmune arthritis. J Clin Invest. 2013;125:134–7.

37. Maresz KJ, Hellvard A, Sroka A, Adamowicz K, Bielecka E, Koziel J, et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog. 2013;9:e1003627.

38. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007;152:429–48.

39. Hajishengallis G, Maekawa T, Abe T, Hajishengallis E, Lambris JD. Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches. Adv Exp Med Biol. 2015;865:57–74.

40. Bostanci N, Belibasakis GN. Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen. FEMS Microbiol Lett. 2012;333:1–9.

41. Marchesan JT, Gerow EA, Schaff R, Taut AD, Shin SY, Sugai J, et al. Porphyromonas gingivalis oral infection exacerbates the development and severity of collagen-induced arthritis. Arthritis Res Ther. 2013;15:R186.

42. Safar K, Takahashi N, Kato T, Matsuura Y, Yokoi M, Yamada M, et al. Aggravation of collagen-induced arthritis by orally administered Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system. Sci Rep. 2017;7:6955.

43. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004;114:582–8.

44. Khun KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006;116:961–73.

45. Uyosl H, Bockermann R, Nandakumar KS, Sehniert B, Bajtner E, Engstrom A, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med. 2009;209:449–62.

46. Trouw LA, Haisma EM, Levernt VW, van der Woude D, Ioan-Facsinay A, Daha MR, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 2009;60:1923–31.

47. Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ. Periodontitis in RA: the citrullinated enolase connection. Nat Rev Rheumatol. 2010;6(12):727–30.

48. Sandal K, Karydis A, Luo J, Prislovsky A, Whittington KB, Rosloniec EF, et al. Bone loss and aggravated autoimmune arthritis in HLA-DRbeta1-bearing humanized mice following oral challenge with Porphyromonas gingivalis. Arthritis Res Ther. 2016;18:249.

49. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov. 2010;9:43–56.

50. Puig-Silla M, Montiel-Company JM, Dasi-Fernandez F, Almirich-Silla JM. Prevalence of periodontal pathogens as predictor of the evolution of periodontal status. Odontology. 2017;105:467–76.